By API User
● Starpharma will employ its proprietary DEP® platform technology to develop dendrimerdrug conjugates that incorporate Genentech medicines for certain oncology targets. ● Starpharma will commence development activities immediately and work exclusively with Genentech in relation to those targets. ● Starpharma will receive an upfront payment of USD $5.5 million (~AUD $8.3 million), and is eligible … Continued
By API User
Wednesday 8 October 2025: The $33 million BioMedTech incubator (BMTI) program delivered by Brandon BioCatalyst’s CUREator has opened its first funding round and is seeking expressions of interest from early-stage Australian biotech startups developing novel therapies with strong commercial potential across the discovery, preclinical, and clinical development stages. Funded by the Australian Government’s $20 billion … Continued
By API User
7 October 2025 – Perth, Australia | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has today announced that the first three patients have been approved for treatment under the Therapeutic Goods Administration (TGA)’s Special Access Program to receive its patented stem cell therapy, StemSmart™, to treat fistulising Crohn’s disease. The patients are now part of Cohort 1 for … Continued
By API User
6 October 2025 – Sydney, Australia | LTR Pharma Limited (ASX:LTP) has increased its ownership in LevOmega Pty Ltd from 33% to ~43% via a strategic $1 million investment. The additional stake was acquired via the Company’s wholly-owned subsidiary, LTR Spectrum Pty Ltd, and follows LevOmega’s successful capital raising to progress its research and development … Continued
By API User
In short: Monash establishes Australian-first ‘Monash Boston Hub’ to advance drug discovery and health innovations; Australia has a strong track record in translating drug discoveries into candidates ready for early stage trials, however global collaboration is often needed to get a new drug to market; The Monash Boston Hub is a vehicle to get new … Continued
By API User
Key Facts: · INOVIQ’s proprietary EXO-ACE platform for scalable CAR-exosome production platform published in Journal of Visualized Experiments (JoVE) · EGFR- and HER2-targeted CAR-T-exosomes demonstrated potent in-vitro cancer-killing activity in breast and myeloid leukemia cell lines · EXO-ACE validated for large-scale production of CAR-EVs, supporting preclinical development INOVIQ Limited (ASX: IIQ) (“INOVIQ” or “the Company“) … Continued
By API User
Sydney, Australia – September 29, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, today announced that it will present six abstracts at the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM), taking place October 4-8, 2025, in Barcelona, Spain. The abstracts present key insights into clinical study … Continued
By API User
Key Facts: · Exclusive worldwide licence secured from UniQuest for novel exosomal ovarian cancer biomarker IP · Supports development and commercialisation of INOVIQ’s EXO-OC test for early detection and screening ovarian cancer in asymptomatic women · Commercial discussions underway with leading clinical laboratories and diagnostic companies to accelerate US LDT launch · Clinical validation advancing, … Continued
By API User
Australia’s biotech capital, Melbourne, has further strengthened its research and development capabilities through a newly formed Memorandum of Understanding (MoU) between Monash University and K-Bio Lab Hub – South Korea’s government-backed biotech incubator. Under the MoU, K-Bio Lab Hub will explore commencing its first Australian launchpad within the Monash Technology Precinct and support biotech startups from … Continued
By API User
Melbourne, Australia – Monday 22 September 2025 – The CUREator + Dementia and Cognitive Decline BioMedTech Incubator today announced seven companies will receive $15,765,871 in non-dilutive funding. With funding from the Australian Federal government’s Department of Health, Disability and Aged Care and the Medical Research Future Fund, CUREator+ supports the development and commercialisation of medical … Continued
